

BRAINSTORM CELL THERAPEUTICS INC

Form 8-K

January 18, 2012

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 17, 2012

Brainstorm Cell Therapeutics Inc.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	333-61610 (Commission File No.)	20-8133057 (IRS Employer Identification No.)
---	------------------------------------	---

605 Third Avenue, 34th Floor New York, NY (Address of principal executive offices)	10158 (Zip Code)
--	---------------------

(646) 666-3188  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01

Regulation FD Disclosure

On January 17, 2012, Brainstorm Cell Therapeutics Inc. (the “Company”) issued a press release announcing that the data from the initial patients in its ALS Phase I/II clinical trial (the “Clinical Trial”) treated with the Company’s NurOwn™ technology did not present any significant side effects and that the NurOwn™ treatment has so far proven to be safe, and shows indications of beneficial clinical effects, such as an improvement in breathing and swallowing ability as well as in muscular power.

The Clinical Trial is being performed at Hadassah Medical Center in Israel in collaboration with the Company and is utilizing the Company’s NurOwn™ technology for growing and modifying autologous adult human stem cells to treat ALS, often referred to as Lou Gehrig's Disease. The study is headed by Prof. Karussis, M.D., Ph.D., who is the head of Hadassah's Multiple Sclerosis Center and a member of the International Steering Committees for Bone Marrow and Mesenchymal Stem Cells Transplantation in Multiple Sclerosis (MS), and a scientific team from the Company headed by Prof. Eldad Melamed. The initial phase of the study is designed to establish the safety of NurOwn™ and will later be expanded to assess efficacy.

The press release is furnished herewith as Exhibit 99.1.

The information contained in this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Form 8-K.

Item 9.01

Financial Statements and Exhibits

The exhibit listed in the Exhibit Index below is filed with this report.

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

January 18, 2012

Brainstorm Cell Therapeutics Inc.

By: /s/ Liat Sossover  
Liat Sossover  
Chief Financial Officer

---

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated January 17, 2012

---